Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective-Reference-Cited by-同舟云学术

Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective

Published:2021-06-09 Issue:9 Volume:39 Page:1045-1058
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Stellato Daniel,Thabane Marroon E.,Park Jinhee,Chandiwana David,Delea Thomas E.^ORCID

Funder

Novartis Pharmaceuticals Corporation

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40273-021-01027-4.pdf

Reference45 articles.

1. Surveillance Epidemiology and End Results Program. Cancer Stat Facts: Female Breast Cancer. National Cancer Institute. 2018. https://seer.cancer.gov/statfacts/html/breast.html. Accessed 11 May 2018.

2. Canadian Cancer Society. Breast Cancer Statistics. 2019. http://www.cancer.ca/en/cancer-information/cancer-type/breast/statistics/?region=on. Accessed 10 Feb 2019.

3. Canadian Cancer Society. Breast Cancer Statistics. 2020. https://www.cancer.ca/en/cancer-information/cancer-type/breast/statistics/?region=on. Accessed 21 May 2020.

4. Cardoso F, et al. 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3). Ann Oncol. 2017;28(12):3111.

5. Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics 2018. Toronto, ON: Canadian Cancer Society. 2018. https://www.cancer.ca/Canadian-Cancer-Statistics-2018-EN. Accessed 12 Dec 2018.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA;PharmacoEconomics;2023-03-15

2. Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women;Applied Health Economics and Health Policy;2022-05-10

3. Role of CDK4/6 inhibitors in patients with hormone receptor (HR)-positive, human epidermal receptor-2 negative (HER-2) metastatic breast cancer study protocol for a systematic review, network meta-analysis and cost-effectiveness analysis;BMJ Open;2022-05